You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 23, 2024

VESICARE LS Drug Patent Profile

✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Vesicare Ls, and what generic alternatives are available?

Vesicare Ls is a drug marketed by Astellas and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has twenty-three patent family members in twenty-one countries.

The generic ingredient in VESICARE LS is solifenacin succinate. There are thirty drug master file entries for this compound. Twenty-seven suppliers are listed for this compound. Additional details are available on the solifenacin succinate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Vesicare Ls

A generic version of VESICARE LS was approved as solifenacin succinate by TEVA PHARMS USA on April 2nd, 2014.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for VESICARE LS?
  • What are the global sales for VESICARE LS?
  • What is Average Wholesale Price for VESICARE LS?
Drug patent expirations by year for VESICARE LS
Drug Prices for VESICARE LS

See drug prices for VESICARE LS

Recent Clinical Trials for VESICARE LS

Identify potential brand extensions & 505(b)(2) entrants

Genuine Research Center, EgyptPhase 1
Hikma PharmaPhase 1
Centre Hospitalier Universitaire VaudoisPhase 4

See all VESICARE LS clinical trials

Pharmacology for VESICARE LS
Paragraph IV (Patent) Challenges for VESICARE LS
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
VESICARE LS Oral Suspension solifenacin succinate 1 mg/mL 209529 1 2021-05-27

US Patents and Regulatory Information for VESICARE LS

VESICARE LS is protected by one US patents.

Patents protecting VESICARE LS

Pharmaceutical composition comprising solifenacin
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astellas VESICARE LS solifenacin succinate SUSPENSION;ORAL 209529-001 May 26, 2020 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for VESICARE LS

See the table below for patents covering VESICARE LS around the world.

Country Patent Number Title Estimated Expiration
Brazil 112012029461 composição farmacêutica contendo solifenacina ⤷  Sign Up
Poland 2572717 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for VESICARE LS

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0801067 04C0032 France ⤷  Sign Up PRODUCT NAME: SUCCINATE DE SOLIFENACINE; NAT. REGISTRATION NO/DATE: NL 30 109 20040816; FIRST REGISTRATION: NL - RVG 29 151 20031216
0801067 C00801067/01 Switzerland ⤷  Sign Up PRODUCT NAME: SOLIFENACIN; REGISTRATION NUMBER/DATE: SWISSMEDIC 57203 12.05.2006
0801067 SPC/GB04/029 United Kingdom ⤷  Sign Up PRODUCT NAME: SOLIFENACIN AND/OR PHARMACEUTICALLY ACTIVE SALT THEREOF; REGISTERED: NL RVG 29151 20031216; NL RVG 29152 20031216; UK PL 00166/0197 20040816; UK PL 0016/0198 20040816
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.